Next Article in Journal
The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study)—A Protocol for an International Cohort Study
Next Article in Special Issue
Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms
Previous Article in Journal
Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing—A Prospective Feasibility Study
Previous Article in Special Issue
The Prevalence of TET2 Gene Mutations in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms (MPN): A Systematic Review and Meta-Analysis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 13
Issue 12
10.3390/cancers13123102
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker

by
Magda Zanelli
1,
Giuseppe G. Loscocco
2,3,
Elena Sabattini
4,
Maurizio Zizzo
5,6,*,
Francesca Sanguedolce
7,
Luigi Panico
8,
Daniela Fanni
9,
Raffaella Santi
10,
Cecilia Caprera
11,
Cristiana Rossi
12,
Alessandra Soriano
13,14,
Alberto Cavazza
1,
Alessandro Giunta
5,
Cristina Mecucci
15,
Alessandro M. Vannucchi
2,3,
Stefano A. Pileri
16 and
Stefano Ascani
11,15
1
Pathology Unit, Azienda Unità Sanitaria Locale—IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy
2
Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy
3
Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliero-Universitaria Careggi, 50139 Florence, Italy
4
Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
5
Surgical Oncology Unit, Azienda Unità Sanitaria Locale—IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy
6
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41121 Modena, Italy
7
Pathology Unit, Azienda Ospedaliero-Universitaria—Ospedali Riuniti di Foggia, 71122 Foggia, Italy
8
Pathology Unit Azienda Ospedaliera dei Colli Monaldi-Cotugno-CTO, P.O. Monaldi, 80131 Napoli, Italy
9
Division of Pathology, Department of Medical Sciences and Public Health, University of Cagliari, 09042 Cagliari, Italy
10
Department of Pathology, Azienda Ospedaliero Universitaria Careggi, University of Florence, 50139 Florence, Italy
11
Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy
12
Pathology Unit, Azienda USL5, 19124 La Spezia, Italy
13
Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA
14
Gastroenterology Unit, Azienda Unità Sanitaria Locale—IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy
15
Haematology Unit, CREO, Azienda Ospedaliera di Perugia, University of Perugia, 06129 Perugia, Italy
16
Haematopathology Division, European Institute of Oncology—IEO IRCCS, 20141 Milan, Italy
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(12), 3102; https://doi.org/10.3390/cancers13123102
Submission received: 31 March 2021 / Revised: 14 June 2021 / Accepted: 18 June 2021 / Published: 21 June 2021
(This article belongs to the Special Issue Pathogenesis and Natural History of Myeloproliferative Neoplasms)
Browse Figures
Versions Notes

Abstract

:

Simple Summary

Rarely, T-lymphoblastic lymphoma (T-LBL) may develop in the setting of myeloid/lymphoid neoplasms with eosinophilia. Given important therapeutic implications, it is crucial to identify T-LBL arising in this particular context. LIM domain only 2 (LMO2) is known to be overexpressed in almost all sporadic T-LBL and not in immature TdT-positive T-cells in the thymus and in indolent T-lymphoblastic proliferations. We retrospectively evaluated the clinical, morphological, immunohistochemical and molecular features of 11 cases of T-LBL occurring in the setting of myeloid/lymphoid neoplasms with eosinophilia and investigated the immunohistochemical expression of LMO2 in this setting of T-LBL. Interestingly, 9/11 cases were LMO2 negative, with only 2 cases showing partial expression. In our study, we would suggest that LMO2 immunostaining, as part of the diagnostic panel for T-LBL, may represent a useful marker to identify T-LBL developing in the context of myeloid/lymphoid neoplasms with eosinophilia.

Abstract

Background: Rarely, T-lymphoblastic lymphoma (T-LBL) may develop in the setting of myeloid/lymphoid neoplasms with eosinophilia (M/LNs-Eo), a group of diseases with gene fusion resulting in overexpression of an aberrant tyrosine kinase or cytokine receptor. The correct identification of this category has relevant therapeutic implications. LIM domain only 2 (LMO2) is overexpressed in most T-LBL, but not in immature TdT-positive T-cells in the thymus and in indolent T-lymphoblastic proliferations (iT-LBP). Methods and Results: We retrospectively evaluated 11 cases of T-LBL occurring in the context of M/LNs-Eo. Clinical, histological, immunohistochemical and molecular features were collected and LMO2 immunohistochemical staining was performed. The critical re-evaluation of these cases confirmed the diagnosis of T-LBL with morphological, immunohistochemical and molecular features consistent with T-LBL occurring in M/LNs-Eo. Interestingly, LMO2 immunohistochemical analysis was negative in 9/11 cases, whereas only 2 cases revealed a partial LMO2 expression with a moderate and low degree of intensity, respectively. Conclusions: LMO2 may represent a potentially useful marker to identify T-LBL developing in the context of M/LNs-Eo. In this setting, T-LBL shows LMO2 immunohistochemical profile overlapping with cortical thymocytes and iT-LBP, possibly reflecting different molecular patterns involved in the pathogenesis of T-LBL arising in the setting of M/LNs-Eo.

1. Introduction

T-lymphoblastic lymphoma (T-LBL) is an aggressive neoplasm of T-lymphoid precursors, which can rarely occur in the setting of M/LNs-Eo [1].
According to the current 2017 World Health Organization (WHO) classification, these disorders represent a distinct, but highly heterogeneous category, comprising cases with rearrangement of platelet-derived growth factor receptor (PDGFR)-alpha (PDGFRA), PDGFR-beta (PDGFRB) and fibroblast growth factor receptor 1 (FGFR1); a provisional entity identified by the presence of pericentriolar material 1-janus kinase 2 (PCM1-JAK2) rearrangement is also included [1,2,3,4]. A pluripotent stem cell is thought to be affected and disease presentation is very heterogeneous, including myeloproliferative neoplasms (MPN), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), acute myeloid leukemia (AML), T- or B-LBL and mixed-phenotype acute leukemia [1,2,3,4]. The diagnosis of these entities requires the identification of the specific gene fusion, with cytogenetic and molecular tests, leading to overexpression of an aberrant tyrosine kinase or cytokine receptor [1,2,3,4]. PDGFRA and PDGFRB rearrangements may be cryptic, but fluorescence in situ hybridization (FISH) and/or RNA/DNA sequencing, either targeting or high-throughput next generation sequencing (NGS)-based are useful tools for diagnosis [1,2,3,4]. The identification of the underlying molecular abnormality is crucial, having important therapeutic implications, given the responsiveness of some of these disorders to tyrosine-kinase inhibitors (TKIs) [1,2,3,4,5]. The response to TKIs is different according to the fusion gene identified, as PDGFRA- and PDGFRB-rearranged cases are responsive, in the majority of cases, to imatinib, which represents the first line therapy, whereas FGFR1-rearranged cases do not respond to imatinib [3,5]. Although lymphoma-like aggressive chemotherapy and hematopoietic stem cell transplantation (HSCT) are considered the best therapeutic option for FGFR1-positive cases, prognosis is very poor in these cases. Clinical trials with new TKIs such as pemigatinib, a potent and selective inhibitor of FGFR family, are ongoing with promising preliminary results [6,7]. In patients with PCM1-JAK2 fusion gene, target therapy with JAK inhibitors such as ruxolitinib may offer a potential benefit [8].
LIM Domain Only 2 (LMO2), also known as rhombotin-like 1, is a highly evolutionary conserved protein involved in scaffolding of transcription factors (including GATA family) necessary for hematopoiesis and angiogenesis [9]. In recent years, it has been demonstrated that LMO2 protein is expressed in normal germinal centers (GCs) and germinal center (GC)-derived lymphomas [10]. Its overexpression has relevant prognostic implications in the context of diffuse large B-cell lymphoma (DLBCL), defining the GC molecular subgroup [11,12,13]. Moreover, LMO2 has been found to be overexpressed in the majority of T-LBL [14,15], but not in immature TdT-positive T-cells in the thymus and in indolent T-lymphoblastic proliferations (iT-LBP), as recently reported [16].

2. Results

The clinic-pathological features of T-LBL occurring in patients affected by M/LNs-Eo are summarized in Table 1. A detailed description of each case, including epidemiology, clinical presentation, treatment, outcome, histological, immunohistochemical and molecular findings, is presented in the Supplementary Material.

2.1. Clinical Characteristics and Laboratory Findings

Patients were mostly males (7/11) and the age at presentation ranged from 19 and 75 years, with a median age of 50.5 years. Five/eleven patients presented with typical constitutional B symptoms: weight loss (4/5), fever (3/5) and sweats (2/5). Asthenia, skin rash and stomatitis were reported at diagnosis in three, two and one patient, respectively. In one patient, the disease presented as skin rash, followed by fever 3 months later. In 3/11 cases, the disease presented with lymphadenopathy which was mostly diffuse; in 5/11, multiple lymphadenopathy occurred in association with splenomegaly; in 1/11 the disease presented with multiple lymphadenopathy, splenomegaly and hepatomegaly; in 1/11 cases, multiple lymphadenopathy developed 3 months after the initial presentation with skin rash; in 1/11, diffuse lymphadenopathy and splenomegaly appeared 2 months after an asymptomatic presentation. Thymus involvement was not observed in any patient. Blood test disclosed leukocytosis with eosinophilia at varying extent; the median white blood cell count (WBC:) and eosinophil count were 40,359/mm3 (range 18,000–72,830) and 7630/mm3 (1800–31,316), respectively. The median hemoglobin level was 12.7 g/dL (range 8.2–17.8) and median platelet count 175,272 (range 43,000–520,000). In 5/11 cases, the lactate dehydrogenase (LDH) level was elevated with a mean value of 610 U/L (range 386–897).

2.2. Bone Marrow Histological and Immunohistochemical Findings

In all cases, bone marrow (BM) biopsy revealed a hypercellular marrow with prevalence of myeloid cells in different stages of maturation and clear-cut increase in eosinophils. CD34-positive hematopoietic precursors were within normal limits (1–2%) in the majority of cases (10/11), with only one case showing increased CD34-positive cells (7%). In most cases (5/11), the erythroid lineage was reduced, with maturation defect and slight predominance of proerythroblasts and basophilic erythroblasts; in 1/11 (case n° 5), large aggregates of immature erythroid precursors along with immature myeloid precursors were noted and in 1/11, trilinear hyperplasia was present. Mild abnormalities were found in the megakaryocytic lineage, with either a mild increase in the number of megakaryocytes in 3/11 cases or a reduction in 1/11; nuclear lobulation defects of megakaryocytes were seen in 3/11 cases. In 4/11 cases, marrow fibrosis ranging from grade 1 to grade 3 was present. A minor B-lymphoblastic component of medium sized cells with high N/C ratio was identified in 2/11 cases, whereas in 1/11 cases, 5–10% of mast cells (tryptase+, CD117+, CD25−) were identified, mainly dispersed and occasionally in tiny paratrabecular aggregates, not meeting the current 2017 WHO criteria for a concomitant diagnosis of systemic mastocytosis (SM).

2.3. T-LBL Histological and Immunohistochemical Findings

In all the cases, the lymph node histology and immunohistochemical profile were consistent with T-LBL diagnosis. The nodal architecture was effaced by a diffuse proliferation of medium-sized cells with dispersed chromatin and scarce cytoplasm (Figure 1) with high proliferative fraction and usually positive for TdT (Figure 2), CD1a and T-cell markers such as CD3 (Figure 3), CD2, CD8, CD5, CD7. B-cell markers (CD79α, CD20, PAX5 and CD22) were mostly negative; a weak CD79α co-expression was noted in 2/11 cases; myeloid (MPO, CD117, CD68KP1) and monocytic (CD68PGM1) markers were negative. In 5/11 cases, a minor component of immature myeloid cells was identified (Figure 4). Aggregates of mature eosinophils (Figure 5) admixed to the lymphoblastic proliferation were noted in 5/11 cases, whereas clusters of proerytroblasts (Figure 6 and Figure 7) were identified within T-LBL in 1/11 cases. Unexpectedly, LMO2 immunostaining was found to be negative in 9/11 T-LBLs (Figure 8); in the remaining 2 cases, LMO2 was partially expressed (less than 30% of cells) with either moderate or low degree of intensity, respectively (Figure 9).

2.4. Molecular Data

The karyotype and FISH analysis (see Supplementary Materials) identified FIP1L1-PDGFRA fusion gene in 2/11 cases, ZMYM2-FGFR1 fusion gene in 5/11, BCR-FGFR1 in 2/11, and PCM1/JAK2 in 1/11, whereas in the remaining 2 cases, any known genetic alteration was identified. Additionally, in case n° 7 (ZMYM2-FGFR1) gene fusion was confirmed by targeted NGS analysis. More detailed information concerning the cytogenetic abnormalities are reported in Supplementary Material.

2.5. Therapy and Outcome

Treatments administered to these patients were highly heterogeneous. The PDGFRA-related cases responded well to imatinib; in particular, the first case of our series is in complete molecular remission (CMR) at 10 years from diagnosis; the second PDGFRA-related case (n° 11) is quite recent and therapy with imatinib is still ongoing with good clinical and laboratory response. The majority of FGFR1-rearranged cases (n° 2, 4, 6, 9, 10) had a poor outcome, despite different intensive chemotherapy schemes. Details are provided in the Supplementary Materials. Case n° 7 represents the only FGFR1-related case with a good outcome, after 2 CVP (cyclophosphamide, vincristine, prednisone) cycles with no benefit, the FGFR-inhibitor pemigatinib was started and is still ongoing with good clinical and laboratory response. In two cases (n° 3 and n° 8) any known genetic alteration was identified; in case n° 3, the empiric treatment with imatinib (100 mg/daily), followed by the maintenance dose (100 mg/weekly) resulted in a complete hematological remission (CHR) at 10 years from diagnosis, despite the persistency of T-cell receptor gamma (TCR-γ) rearrangement by RT-PCR on peripheral blood; in case n° 8, in absence of a known genetic alteration, the chemotherapeutic approach with hyper-CVAD followed by allo-HSCT was used, obtaining a CHR at 5 years. Case n° 5 (PCM1-JAK2-positive) had a poor response to different chemotherapy schemes: 6-mercaptopurine (50 mg/m2/daily) plus low-dose cytarabine (40 mg/m2/daily), then FLAG (fludarabine, cytarabine, granulocyte colony-stimulating factor) with liposomal doxorubicin; due to refractory disease, the patient died before allo-HSCT.

3. Discussion

LMO2 belongs to a multigene family extremely conserved during evolution, containing two cystein-rich regions referred to as LIM domains; it encodes for the homonymous LMO2 protein playing a central role in angiogenesis and required for the development of normal haematopoiesis [9]. The highest expression of LMO2 was observed in normal GC lymphoid B cells, in GC-derived lymphoma and Burkitt lymphoma [10]. Additionally, LMO2 expression has been associated with a favorable prognosis in a subset of DLBCL with GC phenotype [11,12,13]. Conversely, LMO2 protein is not expressed during T-cell development; consequently, T-cell precursors of the thymus and T-cell areas of peripheral lymphoid organs are LMO2 negative [14]. The role of LMO2 as an oncogene capable of inducing T-cell lymphoblastic leukemia has been widely demonstrated in mouse models [17,18]; accordingly, several in vivo studies have suggested the role of LMO2 in the pathogenesis of T-LBL [19]. LMO2 seems to be a specific marker of transformed T-cell precursors compared with their normal counterparts [14]. In T-cell lymphoblastic lymphoma/leukemia, LMO2 overexpression is to a lesser extent attributable to the presence of t(11;14)(p13;q11) or t(7;11)(q35;p13) involving LMO2 gene or to cryptic deletions of negative regulators of its transcription [20,21]. To explain LMO2 overexpression in a large proportion of T-LBL, a more extensive involvement of LMO2 in T-cell precursors tumorigenesis by other still unknown mechanisms has been supposed [14].
T-LBL is an aggressive neoplasm of T-cell precursors, affecting mainly children and young adults and involving lymph nodes, BM and thymus [1]. The standard therapeutic approach for T-LBL involves multiagent chemotherapy regimens [22,23]. However, rare cases of T-LBL may develop in the context of M/LNs-Eo and rearrangement of tyrosine-kinase (TK) genes [1,3]. Accurate diagnosis and classification of T-LBL arising in this particular setting has important therapeutic implications.
The current 2017 WHO classification recognizes the following specific diseases: M/LNs-Eo with rearrangements of PDGFRA, PDGFRB and FGFR1 respectively and the provisional entity of myeloid/lymphoid neoplasms with PCM1-JAK2 rearrangement [1]. In addition to the aforementioned TK fusion genes, rearrangements involving FLT3, ABL1 and LYN genes have also been reported in M/LNs-Eo, although not formally included in the current WHO classification [24,25,26]. The typical presentation of M/LNs-Eo consists of a MPN with associated variable degree of eosinophilia, but clinical manifestations are proteiform [27], involving simultaneously or sequentially the myeloid and or/lymphoid lineages, even in individual patients [1,2,3,4]. Each subtype has a preferential disease presentation and eosinophilia or hypereosinophilia (absolute eosinophilic count of 1.5 × 109 L or more) is common, but not invariably present. PDGFRA-rearranged cases often present as chronic eosinophilic leukemia (CEL) and, less commonly, as AML or T-LBL [1,3,28].
PDGFRB-rearranged cases preferentially manifest as chronic myelomonocytic leukemia (CMML), and less frequently as CEL, MPN or atypical chronic myeloid leukemia (aCML) [1,3,29,30]. In the PDGFRB category, LBL occurrence is rare [1,15]. FGFR1-related cases most often present as T-LBL and less commonly as CEL, B-LBL and AML [1,3,31,32,33]. PCM1-JAK2-related cases can manifest as CEL, aCML, primary myelofibrosis and rarely as AML or B and T-LBL [34].
In the present series, we analyzed the clinic-pathological features of 11 cases of M/LNs-Eo (2 FIP1L1-PDGFRA-rearranged; 5 ZMYM2-FGFR1-rearranged; 1 BCR-FGFR1-rearranged; 1 PCM1/JAK2-related; and 2 without any known genetic alterations). In all the cases, the disease presented as T-LBL associated with MPN and eosinophilia. We observed a different LMO2 expression in T-LBL arising in the setting of M/LNs-Eo compared to sporadic T-LBL.
It is crucial to identify T-LBL occurring in M/LNs-Eo, given the exquisite responsiveness to different TKIs of some of these disorders. Besides some helpful morphological clues (i.e., eosinophils and/or immature myeloid elements in the context of T-LBL [3,35], proerythroblasts admixed to T-LBL, as well as the classical BM “triad” including hypercellularity with eosinophilia, clusters of erythroid precursors and fibrosis in PCM1-JAK2-rearranged cases [3,36]), the immunohistochemical search for LMO2 may represent an aid to identify T-LBL occurring in the setting of M/LNs-Eo.
T-LBL almost universally overexpress LMO2 [14,15]. Unexpectedly, in our series, the majority of T-LBL occurring in the context of M/LNs-Eo was LMO2 negative, with only 2 cases showing partial LMO2 expression with moderate and low degree of intensity, respectively. Jevremovic et al. reported that LMO2 represents a marker commonly expressed by T-LBL and absent in thymocytes of normal thymus and thymomas [15]. Since there is no specific immunophenotypic profile to distinguish thymocytes or thymic epithelial tumors from neoplastic T lymphoblasts, LMO2 is currently considered a useful marker in discriminating thymoma from T-LBL, being almost universally expressed in T-LBL [15]. Recently Brar et al. identified LMO2 as a sensitive and specific marker for differentiating T-LBL from iT-LBP, which were found to be LMO2-negative [16]. The absence of LMO2 expression in iT-LBP was considered by Brar et al. consistent with a thymic origin for iT-LBP as T-lymphoblasts in the thymus do not express LMO2 [16].
In our study, we would suggest that LMO2 immunostaining, as part of the diagnostic panel for T-LBL, may represent a potentially useful marker to identify T-LBL developing in the context of M/LNs-Eo. In this particular setting, T-LBL shows an immunohistochemical profile overlapping with cortical thymocytes and iT-LBP, possibly reflecting different molecular patterns involved in the pathogenesis of T-LBL arising in the setting of M/LNs-Eo.

4. Materials and Methods

We retrospectively collected clinical, histopathological and molecular data of 11 cases of T-LBL, occurring in the setting of M/LNs-Eo, diagnosed at six of our institutions between 2006 and 2020. All data were critically re-evaluated, according to the latest 2017 WHO criteria [1]. Cytogenetic and molecular analyses were performed at respective institutions at the time of diagnosis as part of the routine clinical work-up. 4-μm-thick sections were cut from formalin-fixed and paraffin-embedded blocks of lymph nodes with T-LBL. Immunohistochemical tests included the determination of LMO2. In 10/11 cases, the anti-LMO2 antibody clone SP51 (Spring Bioscience, Pleasanton, CA, USA) was applied at a dilution 1:400 for 30 min, following antigen retrieval in a PT link at 92 °C (high pH solution) for 5 min. The detection system used was the ultra-view CC1 on a Ventana platform (Ventana Medical Systems, Oro Valley, AZ, USA) in 8/11 cases and the Dako REAL detection system Alkaline Phosphatase/RED on a Dako AutoStainer Plus (Agilent Dako, Santa Clara, CA, USA) in the remaining two. In one further case, the LMO2 antibody used was LMO2, clone 1A9-1 (Roche, Basel, Switzerland), undiluted, CC1 37 °C (high pH) 32 min + 30 min of primary antibody incubation, with detection system Opti-VIEW Universal DAB detection Kit, platform Bench Mark Ultra (Ventana Medical Systems, Inc., Oro Valley, AZ, USA).
To reduce bias in data analysis, immunohistochemical results were blindly re-evaluated at two institutions (Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, Terni, Italy and Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy). No discrepancies were recorded between the estimates at the two Institutions.

5. Conclusions

To the best of our knowledge, this is the first study investigating LMO2 expression by immunohistochemistry in T-LBL cases arising in the context of M/LNs-Eo. On the basis of our findings, immunohistochemical LMO2 expression, along with some morphological clues, may help to identify cases of T-LBL in the setting of M/LNs-Eo, stating that this group of disorders may be easily underdiagnosed due to both its rarity and proteiform clinical presentation. In conclusion, our study may be considered an exploratory analysis for more extensive studies including further cases and more in-depth molecular analysis to better address the frequent negative LMO2 immunohistochemical expression in T-LBL developing in the context of M/LNs-Eo.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/cancers13123102/s1, Text S1: Presentation of the eleven clinical cases.

Author Contributions

Conceptualization, M.Z. (Magda Zanelli) and S.A.; Methodology, M.Z. (Magda Zanelli) and G.G.L.; Validation, E.S., C.M., A.M.V., S.A.P., S.A.; Formal analysis, M.Z. (Magda Zanelli) and G.G.L.; Investigation, E.S. and S.A.; Data curation, G.G.L., E.S., M.Z. (Maurizio Zizzo), F.S., L.P., D.F., R.S., C.C., C.R., A.S., A.C., A.G. and S.A.; Writing—original draft preparation, M.Z. (Magda Zanelli); Writing—review and editing, M.Z. (Maurizio Zizzo); Supervision, E.S., C.M., A.M.V., S.A.P., S.A.; Project administration, M.Z. (Magda Zanelli) and M.Z. (Maurizio Zizzo). All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by AIRC 5 × 1000 called “Metastatic disease: the key unmet need in oncology” to MINERVA project, 21267/Myeloid Neoplasms Research Venture AIRC) for G.G.L., C.M. and A.M.V.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patient(s) or their relatives to publish this paper.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J. (Eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed.; IARC: Lyon, France, 2017. [Google Scholar]
  2. Shomali, W.; Gotlib, J. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am. J. Hematol. 2019, 94, 1149–1167. [Google Scholar] [CrossRef] [Green Version]
  3. Pozdnyakova, O.; Orazi, A.; Kelemen, K.; King, R.; Reichard, K.K.; E Craig, F.; Quintanilla-Martinez, L.; Rimsza, L.; I George, T.; Horny, H.-P.; et al. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2. Am. J. Clin. Pathol. 2021, 155, 160–178. [Google Scholar] [CrossRef]
  4. Mattis, D.M.; A Wang, S.; Lu, C.M. Contemporary Classification and Diagnostic Evaluation of Hypereosinophilia. Am. J. Clin. Pathol. 2020, 154, 305–318. [Google Scholar] [CrossRef] [PubMed]
  5. Gotlib, J. Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis. Hematol. Clin. N. Am. 2017, 31, 643–661. [Google Scholar] [CrossRef] [PubMed]
  6. Verstovsek, S.; Subbiah, V.; Masarova, L.; Yin, C.C.; Tang, G.; Manshouri, T.; Asatiani, E.; Daver, N. Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. Ann. Oncol. 2018, 29, 1880–1882. [Google Scholar] [CrossRef]
  7. Verstovsek, S.; Vannucchi, A.M.; Rambaldi, A.; Gotlib, M.J.R.; Mead, A.J.; Hochhaus, A.; Kiladjian, J.-J.; Boluda, J.C.H.; Asatiani, E.; Lihou, B.C.; et al. Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1). Blood 2018, 132, 690. [Google Scholar] [CrossRef]
  8. Rumi, E.; Milosevic, J.D.; Selleslag, D.; Casetti, I.; Lierman, E.; Pietra, D.; Cavalloni, C.; Bellini, M.; Milanesi, C.; Dambruoso, I.; et al. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Ann. Hematol. 2015, 94, 1927–1928. [Google Scholar] [CrossRef]
  9. Matthews, J.M.; Lester, K.; Joseph, S.; Curtis, D.J. LIM-domain-only proteins in cancer. Nat. Rev. Cancer 2013, 13, 111–122. [Google Scholar] [CrossRef]
  10. Natkunam, Y.; Zhao, S.; Mason, D.Y.; Chen, J.; Taidi, B.; Jones, M.; Hammer, A.S.; Dutoit, S.H.; Lossos, I.S.; Levy, R. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood 2006, 109, 1636–1642. [Google Scholar] [CrossRef]
  11. Vazquez, I.; Papaleo, N.; Garcia, E.; Salido, M.; Salar, A.; Hernandez, S.; Calvo, X.; Colomo, L. Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas. Cancers 2020, 12, 884. [Google Scholar] [CrossRef] [Green Version]
  12. Natkunam, Y.; Farinha, P.; Hsi, E.D.; Hans, C.P.; Tibshirani, R.; Sehn, L.H.; Connors, J.M.; Gratzinger, D.; Rosado, M.; Zhao, S.; et al. LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. J. Clin. Oncol. 2008, 26, 447–454. [Google Scholar] [CrossRef] [PubMed]
  13. Lossos, I.S.; Czerwinski, D.K.; Alizadeh, A.A.; Wechser, M.A.; Tibshirani, R.; Botstein, D.; Levy, R. Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes. N. Engl. J. Med. 2004, 350, 1828–1837. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Agostinelli, C.; Paterson, J.C.; Gupta, R.; Righi, S.; Sandri, F.; Piccaluga, P.P.; Bacci, F.; Sabattini, E.; A Pileri, S.; Marafioti, T. Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody. Histopathology 2012, 61, 33–46. [Google Scholar] [CrossRef] [PubMed]
  15. Jevremovic, D.; Roden, A.C.; Ketterling, R.P.; Kurtin, P.J.; McPhail, E. LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma. Am. J. Clin. Pathol. 2016, 145, 180–190. [Google Scholar] [CrossRef]
  16. Brar, N.; Butzmann, A.; Kumar, J.; Peerani, R.; Morgan, E.A.; Grigoriadis, G.; Kumar, B.; Tatarczuch, R.M.; Warnke, R.A.; Ohgami, R.S. LIM domain only 2 (LMO2) expression distinguishes T-lymphoblastic leukemia/lymphoma from indolent T-lymphoblastic proliferations. Histopathology 2020, 77, 984–988. [Google Scholar] [CrossRef]
  17. Larson, R.C.; Lavenir, I.; Larson, T.A.; Baer, R.; Warren, A.J.; Wadman, I.; Nottage, K.; Rabbitts, T.H. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J. 1996, 15, 1021–1027. [Google Scholar] [CrossRef]
  18. McCormack, M.P.; Young, L.F.; Vasudevan, S.; De Graaf, C.A.; Codrington, R.; Rabbitts, T.H.; Jane, S.M.; Curtis, D.J. The Lmo2 Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal. Science 2010, 327, 879–883. [Google Scholar] [CrossRef]
  19. McCormack, M.P.; Rabbitts, T.H. Activation of the T-Cell OncogeneLMO2after Gene Therapy for X-Linked Severe Combined Immunodeficiency. N. Engl. J. Med. 2004, 350, 913–922. [Google Scholar] [CrossRef]
  20. Van Vlierberghe, P.; Van Grotel, M.; Beverloo, H.B.; Lee, C.; Helgason, T.; Buijs-Gladdines, J.; Passier, M.; Van Wering, E.R.; Veerman, A.J.P.; Kamps, W.A.; et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood 2006, 108, 3520–3529. [Google Scholar] [CrossRef]
  21. Van Vlierberghe, P.; Beverloo, H.B.; Buijs-Gladdines, J.; Van Wering, E.R.; Horstmann, M.; Pieters, R.; Meijerink, J.P.P. Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia. Leukemia 2007, 22, 1434–1437. [Google Scholar] [CrossRef]
  22. Bassan, R.; Maino, E.; Cortelazzo, S. Lymphoblastic lymphoma: An updated review on biology, diagnosis, and treatment. Eur. J. Haematol. 2016, 96, 447–460. [Google Scholar] [CrossRef] [Green Version]
  23. You, M.J.; Medeiros, L.J.; Hsi, E.D. T-Lymphoblastic Leukemia/Lymphoma. Am. J. Clin. Pathol. 2015, 144, 411–422. [Google Scholar] [CrossRef] [PubMed]
  24. Reiter, A.; Gotlib, J. Myeloid neoplasms with eosinophilia. Blood 2017, 129, 704–714. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Gerds, A.T.; Gotlib, J.; Bose, P.; Deininger, M.W.; Dunbar, A.; Elshoury, A.; George, T.I.; Gojo, I.; Gundabolu, K.; Hexner, E.; et al. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2020, 18, 1248–1269. [Google Scholar] [CrossRef]
  26. Shao, H.; Wang, W.; Song, J.; Tang, G.; Zhang, X.; Tang, Z.; Srivastava, J.; Shah, B.; Medeiros, L.J.; Zhang, L. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement. Leuk. Res. 2020, 99, 106460. [Google Scholar] [CrossRef] [PubMed]
  27. Zanelli, M.; Smith, M.; Zizzo, M.; Carloni, A.; Valli, R.; De Marco, L.; Foroni, M.; Palicelli, A.; Martino, G.; Ascani, S. A tricky and rare cause of pulmonary eosinophilia: Myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA. BMC Pulm. Med. 2019, 19, 216. [Google Scholar] [CrossRef]
  28. Metzgeroth, G.; Walz, C.; Score, J.; Siebert, R.; Schnittger, S.; Haferlach, C.; Popp, H.; Erben, P.; Mix, J.; Müller, M.C.; et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007, 21, 1183–1188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Vega, F.; Medeiros, L.J.; Bueso-Ramos, C.E.; Arboleda, P.; Miranda, R.N. Hematolymphoid Neoplasms Associated With Rearrangements of PDGFRA, PDGFRB, and FGFR1. Am. J. Clin. Pathol. 2015, 144, 377–392. [Google Scholar] [CrossRef] [PubMed]
  30. Arefi, M.; García, J.L.; Peñarrubia, M.J.; Queizán, J.A.; Hermosín, L.; López-Corral, L.; Megido, M.; Giraldo, P.; Heras, N.D.L.; Vanegas, R.J.; et al. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement. Eur. J. Haematol. 2012, 89, 37–41. [Google Scholar] [CrossRef]
  31. Jackson, C.C.; Medeiros, L.J.; Miranda, R.N. 8p11 myeloproliferative syndrome: A review. Hum. Pathol. 2010, 41, 461–476. [Google Scholar] [CrossRef]
  32. Macdonald, D.; Reiter, A.; Cross, N.C. The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of FGFR1. Acta Haematol. 2002, 107, 101–107. [Google Scholar] [CrossRef]
  33. Strati, P.; Tang, G.; Duose, D.Y.; Mallampati, S.; Luthra, R.; Patel, K.P.; Hussaini, M.; Mirza, A.-S.; Komrokji, R.S.; Oh, S.; et al. Myeloid/lymphoid neoplasms withFGFR1rearrangement. Leuk. Lymphoma 2018, 59, 1672–1676. [Google Scholar] [CrossRef]
  34. Bain, B.J.; Ahmad, S. Should myeloid and lymphoid neoplasms withPCM1-JAK2and other rearrangements ofJAK2be recognized as specific entities? Br. J. Haematol. 2014, 166, 809–817. [Google Scholar] [CrossRef] [PubMed]
  35. Vega, F.; Medeiros, L.J.; Davuluri, R.; Cromwell, C.C.; Alkan, S.; Abruzzo, L.V. t(8;13)-positive Bilineal Lymphomas. Am. J. Surg. Pathol. 2008, 32, 14–20. [Google Scholar] [CrossRef] [PubMed]
  36. Tang, G.; Philip, J.K.S.S.; Weinberg, O.; Tam, W.; Sadigh, S.; Lake, J.I.; Margolskee, E.M.; Rogers, H.J.; Miranda, R.N.; Hsi, E.D.; et al. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: A multicenter study. Mod. Pathol. 2018, 32, 490–498. [Google Scholar] [CrossRef] [PubMed]
Cancers 13 03102 g001 550
Figure 1. T-LBL medium-sized cells with high nuclear-cytoplasmic ratio and dispersed chromatin (case 5, Giemsa staining, magnification 400×).
Figure 1. T-LBL medium-sized cells with high nuclear-cytoplasmic ratio and dispersed chromatin (case 5, Giemsa staining, magnification 400×).
Cancers 13 03102 g001
Cancers 13 03102 g002 550
Figure 2. Lymphoblastic proliferation diffusely expressing TdT (case 5, magnification 400×).
Figure 2. Lymphoblastic proliferation diffusely expressing TdT (case 5, magnification 400×).
Cancers 13 03102 g002
Cancers 13 03102 g003 550
Figure 3. CD3 positivity of T-LBL (case 5, magnification 400×).
Figure 3. CD3 positivity of T-LBL (case 5, magnification 400×).
Cancers 13 03102 g003
Cancers 13 03102 g004 550
Figure 4. Immature myeloid cells, admixed to T-LBL, highlighted by myeloperoxidase (MPO) immunostaining (case 7, magnification 200×).
Figure 4. Immature myeloid cells, admixed to T-LBL, highlighted by myeloperoxidase (MPO) immunostaining (case 7, magnification 200×).
Cancers 13 03102 g004
Cancers 13 03102 g005 550
Figure 5. T-LBL containing a discrete component of eosinophils (within red circles) (case 7, Hematoxylin-Eosin staining, magnification 400×).
Figure 5. T-LBL containing a discrete component of eosinophils (within red circles) (case 7, Hematoxylin-Eosin staining, magnification 400×).
Cancers 13 03102 g005
Cancers 13 03102 g006 550
Figure 6. Aggregates of proerythroblasts in the context of T-LBL, in the PCM1-JAK2 rearranged case (case 5, Giemsa staining, magnification 400×).
Figure 6. Aggregates of proerythroblasts in the context of T-LBL, in the PCM1-JAK2 rearranged case (case 5, Giemsa staining, magnification 400×).
Cancers 13 03102 g006
Cancers 13 03102 g007 550
Figure 7. Glycophorin C highlighting proerythroblasts within T-LBL, in the PCM1-JAK2 rearranged case (case 5, immunostaining, magnification 400×).
Figure 7. Glycophorin C highlighting proerythroblasts within T-LBL, in the PCM1-JAK2 rearranged case (case 5, immunostaining, magnification 400×).
Cancers 13 03102 g007
Cancers 13 03102 g008 550
Figure 8. LMO2 negativity of T-LBL; endothelial cells as positive LMO2 controls (case 1, immunostaining, magnification 400×).
Figure 8. LMO2 negativity of T-LBL; endothelial cells as positive LMO2 controls (case 1, immunostaining, magnification 400×).
Cancers 13 03102 g008
Cancers 13 03102 g009 550
Figure 9. Partial and weak LMO2 expression of T-LBL (case 2, immunostaining, magnification 400×).
Figure 9. Partial and weak LMO2 expression of T-LBL (case 2, immunostaining, magnification 400×).
Cancers 13 03102 g009
Table
Table 1. Clinic-pathological features of T-LBL cases in M/LNs-Eo.
Table 1. Clinic-pathological features of T-LBL cases in M/LNs-Eo.
Case: Age/SexClinical PresentationPeripheral BloodBM Histology/
Lymph Node Histology		LMO2 ExpressionMolecular Analyses (on BM)Fusion Gene Therapy Outcome
Case 1: 75/MDyspnea, asthenia, weight loss, skin rash, splenomegaly, lymphadenopathy (axillary, inguinal)WBC: 20,200
Eo: 12,400
PTL: 138,000
Hb: 8.2
MCV: 109		CEL. Grade 3 fibrosis.
T-LBL with minor immature myeloid component		Negative46XY
del(4)(q12;q12)
BCR/ABL1 negative JAK2V617F negative Chromosome 16 inversion negative		FIP1L1-PDGFRAImatinib (100 mg/die × 2 days; then 200 mg/die);
maintenance therapy with CMR at 10 yrs
Case 2: 66/FSplenomegaly, diffuse lymphadenopathyWBC: 25,600
N: 19,200
M: 1024
Eo: 3072
RBC: 6,820,000
Hb: 15.9
HCT: 49.5
PTL 387,000
LDH: 527		MPN with eosinophilia. Grade 1 fibrosis.
T-LBL		Weak and partial46XY t(8;13)(p11;q12)
BCR/ABL1 negative JAK2/V617F negative FI1L1-PDGFRA negative		ZMYM2-FGFR1Hyper-CVAD Exitus at 2 mo
Case 3: 40/MSkin rash.
3 mos later: skin papules, fever; lymphadenopathy (cervical, inguinal)		WBC: 28,880
N: 59%
L: 21
M: 4%
Eo: 7%
My 4%: Meta 5%
Hb: 10.8
PTL 180,000
3 mos later:
WBC: 42,420
N: 31,391
Eo: 6363
Hb: 10.5		Reactive myeloid hyperplasia in d.d. with CML
T-LBL with Eo		NegativeTCRγ +
BCR/ABL1 negative JAK2V617F negative MPL negative
PDGFRA negative TET2/4q24 negative PDGFRB/5q33 negative
FGFR1/8p21 negative
JAK2/9p24 negative ETV6/12p13 negative		Unknown genetic alterationImatinib (100 mg/die);
maintenance therapy (100 mg/weekly)
CHR at 10 years
Case 4: 56/MDiffuse lymphadenopathyWBC: 57,000
N: 33,000
L: 5800
M: 8900
Eo: 8600
PTL: 178,000
Hb: 13.3
LDH 897		MPN with
eosinophilia + B-LBL component.
T-LBL with Eo		Negative46XY t(8;13)(q24;q12); del(9)(q22) der(5)
BCR/ABL1 negative JAK2V617F negative PDGFRA negative MYC(8q24) negative TCRγ negative		ZMYM2-FGFR1No therapy.
Exitus shortly after diagnosis
Case 5: 19/MLymphadenopathy (cervical, sub-mandibular), splenomegaly. Then diffuse lymphadenopathyWBC: 61,440
N: 46,990
M: 3330
L: 6850
Eo: 3330
B: 1610
Hb: 12.9
PTL: 85,000
LDH: 658		MPN with eosinophilia+ erythroid precursors + fibrosis
T-LBL with Eo and proerythroblasts		Negativet(8;12)
BCR/ABL1 negative PDGFRA negative
PDGFRB negative
FGFR1 negative		PCM1/JAK26-mercapto (50/mg/m2/die) + Cyta. (40/mg/m2/die): hydroxyurea + prednisone; FLAG + Myocet. Exitus before allo-HSCT
Case 6: 19/MStomatitis, fever, diffuse lymphadenopathy splenomegaly, hepatomegalyWBC: 18,000 with neutrophilia eosinophilia (3600) left shifting
PTL: 80,000
Hb: 12		MPN with
eosinophilia
T-LBL with Eo and minor immature myeloid component		Negativet(8;13)(p11;q12) t(14;21)(q22;q22) t(8;13)
IGH + IGL + TCRγ+		ZMYM2-FGFR1GRAAL-LYSA LL03 + allo-HSCT
CMR, then AML with exitus despite salvage CT
Case 7: 74/FFever, night sweats, weight loss, lymphadenopathy (cervical)WBC: 42,000
N: 28,700
Eo: 5300
B: 600
PTL: 50.00
Hb: 13
LDH: 386		MPN with eosinophilia +
B-LBL component + mast cells (5–10%). Grade 2 fibrosis
T-LBL with Eo and minor immature myeloid component		Negativet(8;13)(p11;q12)
BCR/ABL1 negative PDGFRA negative PDGFRB negative
KIT D816V negative		ZMYM2-FGFR1CVP (2 cycles) with no benefit. Pemigatinib (ongoing) with benefit.
Case 8: 49/MAsthenia, sweats, weight loss, splenomegaly, diffuse lymphadenopathyWBC: 47,000
N: 40%
prom: 4% My: 8%
Meta: 8%
Eo: 3.20
Hb: 13.8
PTL: 520,000		MPN with eosinophilia
T-LBL + minor immature myeloid component		NegativeNormal 46XY karyotype BCR/ABL1 negative
PDGFRA NP
PDGFRB NP FGFR1 NP		Not detectedHyper-CVAD + allo-HSCT. cGVHD (steroid, rituximab) CHR at 5 yrs. Mycophenolate mofetil + extracorporeal photopheresis (for cGVHD)
Case 9: 49/FLymphadenopathy (cervical)Hb: 17.8
HCT: 54%
WBC: 31,000
Eo: 30%
PTL: 217,000
LDH: 586		MPN with eosinophilia
T-LBL		Negativet(8;13)(p11;q12)ZMYM2-FGFR1Hyper-CVAD, then Cyta
(3 g/m2) followed by busulfan plus cycloph and autologous HSCT; then anti-CD52 therapy. Disease progression with exitus in 2 mos
Case 10: 51/FAsymptomatic at presentation. Hydroxyurea with no benefit; 2 mos later: diffuse lymphadenopathy, splenomegalyWBC: 40,000
Eo: 1800
PTL: 43,000
Hb: 12
FC: aberrant T-cell population (7.89%): CD7+ sCD3− CD4−/+ CD8+ CD16− CD56+ CD5+ CD2+ cyCD3+		MPN/MDS with 7% CD34+
T-LBL + minor immature myeloid component		Moderate/
partial		4 clones: t(8;22)(p11;q11); t(8;22)(p11;q11)+
trisomy 19; der(22)+ t(8;22)(p11;q11)+ trisomy 19
normal XX clone BCR/ABL1 negative MPL negative JAK2V617F negative		BCR-FGFR1Hydroxyurea. Due to lymphadenopathy (T-LBL) and splenomegaly Hyper-CVAD with transient response; FLA with no response and
exitus
Case 11: 58/MAsthenia, fever, weight loss, lymphadenopathy, splenomegalyWBC: 72.8
N: 34%
L: 5% Eo: 43%
Hb: 10.6
PTL: 50,000;
then progressive anemia (Hb: 9) and Eo: 30,000		MPN with eosinophilia
T-LBL		NegativeFIP1L1-PDGFRA positive
CR/ABL1 negative
JAK2V617F negative
Calreticulin negative MPL negative		FIP1L1-PDGFRAImatinib (100 mg) still ongoing with Eo. count decrease (170) and lymphadenopathy reduction
allo-HSCT: allogenic hematopoietic stem cell transplantation; AML: acute myeloid leukemia; B-LBL: B-lymphoblastic lymphoma; BM: bone marrow; CEL: chronic eosinophilic leukemia; CHR: complete hematological remission; CML: chronic myeloid leukemia; CMR: complete molecular remission; cGVHD: chronic graft versus host disease; Cycloph: cyclophosphamide; Cyta: Cytarabine; CT: chemotherapy; DD: differential diagnosis; EBER: Epstein Barr virus encoded RNA; Eo: eosinophils; FC: flow cytometry; FLA: fludarabine plus cytarabine; FLAG: fludarabine, cytarabine, granulocyte-colony stimulating factor; GRAAL-LYSA LM03: vincristine, daunorubicin, cyclophosphamide, L-asparaginase, methotrexate, cytarabine, depo-medrol; Hb: hemoglobin; HCT: hematocrit; Hyper-CVAD: cyclophoshamide, dexamethasone, methotrexate, doxorubicin, vincristine, cytarabine; HSCT: hematopoietic stem cell transplantation; IGH: immunoglobulin heavy chain; IGL: immunoglobulin light chain; L: lymphocytes; 6-mercapto: 6-mercaptopurine; MCV: mean corpuscular volume; MDS/MPN: myelodysplastic/myeloproliferative neoplasms; Meta: metamyelocytes; mod: moderate; M/LNs-Eo: myeloid/lymphoid neoplasms with eosinophilia; M: monocytes; My: myelocytes; Myocet: nonpegylated liposomal doxorubin; Mo: month; Mos: months; MPN: myeloproliferative neoplasm; N: neutrophils; Neg: negative; NP: not performed; prom: promyelocytes; Pos: positive; PTL: platelets; RBC: red blood cell; TCR: T-cell receptor; T-LBL: T-lymphoblastic lymphoma; WBC: white blood cells; yrs: years.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Zanelli, M.; Loscocco, G.G.; Sabattini, E.; Zizzo, M.; Sanguedolce, F.; Panico, L.; Fanni, D.; Santi, R.; Caprera, C.; Rossi, C.; et al. T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker. Cancers 2021, 13, 3102. https://doi.org/10.3390/cancers13123102

AMA Style

Zanelli M, Loscocco GG, Sabattini E, Zizzo M, Sanguedolce F, Panico L, Fanni D, Santi R, Caprera C, Rossi C, et al. T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker. Cancers. 2021; 13(12):3102. https://doi.org/10.3390/cancers13123102

Chicago/Turabian Style

Zanelli, Magda, Giuseppe G. Loscocco, Elena Sabattini, Maurizio Zizzo, Francesca Sanguedolce, Luigi Panico, Daniela Fanni, Raffaella Santi, Cecilia Caprera, Cristiana Rossi, and et al. 2021. "T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker" Cancers 13, no. 12: 3102. https://doi.org/10.3390/cancers13123102

APA Style

Zanelli, M., Loscocco, G. G., Sabattini, E., Zizzo, M., Sanguedolce, F., Panico, L., Fanni, D., Santi, R., Caprera, C., Rossi, C., Soriano, A., Cavazza, A., Giunta, A., Mecucci, C., Vannucchi, A. M., Pileri, S. A., & Ascani, S. (2021). T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker. Cancers, 13(12), 3102. https://doi.org/10.3390/cancers13123102

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop